Winton Group LTD Mei Pharma, Inc. Transaction History

Winton Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$2.33 - $3.37 $66,731 - $96,516	-28,640 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$2.52 - $2.99 $5,601 - $6,646	-2,223 Reduced 7.2%	28,640 $79,000
Q2 2021 Aug 10, 2021	BUY	$2.6 - $3.65 $12,318 - $17,293	4,738 Added 18.14%	30,863 $88,000
Q1 2021 Jul 21, 2021	SELL	$2.73 - $4.5 $2,424 - $3,996	-888 Reduced 3.29%	26,125 $90,000
Q4 2020 Feb 12, 2021	SELL	$2.6 - $3.32 $265,928 - $339,569	-102,280 Reduced 79.11%	27,013 $71,000
Q3 2020 Oct 30, 2020	SELL	$2.46 - $4.27 $138,156 - $239,807	-56,161 Reduced 30.28%	129,293 $403,000
Q2 2020 Aug 05, 2020	SELL	$1.45 - $4.3 $36,505 - $108,256	-25,176 Reduced 11.95%	185,454 $766,000
Q1 2020 May 11, 2020	SELL	$0.75 - $2.55 $35,839 - $121,854	-47,786 Reduced 18.49%	210,630 $339,000
Q4 2019 Feb 13, 2020	SELL	$1.65 - $2.48 $292,878 - $440,204	-177,502 Reduced 40.72%	258,416 $641,000
Q3 2019 Nov 08, 2019	BUY	$1.48 - $2.52 $645,158 - $1.1 Million	435,918 New	435,918 $732,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.